Magda Kowaleczko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Magda Kowaleczko has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Bartłomiej Baszun
University Clinical Hospital No. 1, Lublin, Poland
4 shared publications - Dawid Żuraw
University Clinical Hospital No. 1, Lublin, Poland
4 shared publications - Karolina Klusek
Medical University of Lublin, Poland
4 shared publications - Katarzyna Kulszo
Student Research Group at The Department of Radiotherapy, Medical University of Lublin, Lublin, Poland; Cardinal Stefan Wyszyński Provincial Specialist Hospital, Lublin, Poland
4 shared publications - Krzysztof Mirkowski
Medical University of Lublin, Poland
4 shared publications - Maciej Wiśniecki
Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Poland
4 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
SLEEP DISORDERS AS A RISK FACTOR FOR HYPERTENSION
Sleep disorders are among the most prevalent health problems in modern society and are increasingly recognized as an important risk factor for cardiovascular diseases. Growing evidence indicates that insufficient sleep duration, poor sleep quality, and conditions such as insomnia or obstructive sleep apnea may contribute to the development of arterial hypertension. Sleep plays a crucial role in maintaining systemic homeostasis by regulating neurological, endocrine, and metabolic functions. Sleep disturbances may lead to chronic activation of the sympathetic nervous system and the hypothalamic–pituitary–adrenal (HPA) axis, promoting inflammatory processes and impairing blood pressure regulation. An increasing body of evidence suggests that impaired sleep negatively affects overall health and may contribute to the development of multiple chronic diseases. Sleep disturbances frequently coexist with other cardiovascular risk factors, including chronic stress, obesity, physical inactivity, and unhealthy dietary habits, thereby amplifying their adverse effects. Persistent deterioration in sleep quality may result in metabolic, hormonal, and cardiovascular dysfunction, increasing the risk of long-term health complications and reducing quality of life. In light of current evidence, adequate sleep duration and quality should be considered essential components of hypertension prevention and public health promotion strategies.
- 21 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
Open AccessSLEEP DISORDERS AS A RISK FACTOR FOR HYPERTENSION
Sleep disorders are among the most prevalent health problems in modern society and are increasingly recognized as an important risk factor for cardiovascular diseases. Growing evidence indicates that insufficient sleep duration, poor sleep quality, and conditions such as insomnia or obstructive sleep apnea may contribute to the development of arterial hypertension. Sleep plays a crucial role in maintaining systemic homeostasis by regulating neurological, endocrine, and metabolic functions. Sleep disturbances may lead to chronic activation of the sympathetic nervous system and the hypothalamic–pituitary–adrenal (HPA) axis, promoting inflammatory processes and impairing blood pressure regulation. An increasing body of evidence suggests that impaired sleep negatively affects overall health and may contribute to the development of multiple chronic diseases. Sleep disturbances frequently coexist with other cardiovascular risk factors, including chronic stress, obesity, physical inactivity, and unhealthy dietary habits, thereby amplifying their adverse effects. Persistent deterioration in sleep quality may result in metabolic, hormonal, and cardiovascular dysfunction, increasing the risk of long-term health complications and reducing quality of life. In light of current evidence, adequate sleep duration and quality should be considered essential components of hypertension prevention and public health promotion strategies.
- Open Access
- 4 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
IS RADIATION THERAPY STILL USED IN THE TREATMENT OF GASTRIC CANCER?
Gastric cancer is one of the most prominent global health challenges. Despite recent declines in incidence and mortality, this cancer remains the fifth most commonly diagnosed cancer and the third leading cause of cancer-related deaths worldwide. The treatment of gastric cancer requires a multidisciplinary approach, the choice of which depends on the stage of the disease and the patient’s overall condition. The mainstay of treatment is surgical resection with D2 lymphadenectomy and adjuvant or neoadjuvant radio- and chemotherapy. Currently, radiation therapy is widely used in several critical areas of gastric cancer treatment. Aim: The aim of this study is to evaluate the current use and effectiveness of radiotherapy in the treatment of gastric cancer, as well as the prospects for the further development of this therapeutic method. Material and methods: This study is based on a systematic review of several dozen scientific publications identified through PubMed and Google Schoolar databases using keywords “gastric cancer”, “radiotherapy”, “chemoradiotherapy”. Conclusions: In clinical practice, radiotherapy is primarily used as an adjuvant treatment. In perioperative therapy, it is combined with chemotherapy before surgery to reduce tumor size and after surgery to reduce the risk of recurrence and the development of micrometastases. Additionally, it is used as a palliative treatment for patients with advanced-stage disease who are not eligible for surgery. Emerging evidence also suggests potential benefits of incorporating radiotherapy into the management of patients with limited metastatic disease.
- 4 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessIS RADIATION THERAPY STILL USED IN THE TREATMENT OF GASTRIC CANCER?
Gastric cancer is one of the most prominent global health challenges. Despite recent declines in incidence and mortality, this cancer remains the fifth most commonly diagnosed cancer and the third leading cause of cancer-related deaths worldwide. The treatment of gastric cancer requires a multidisciplinary approach, the choice of which depends on the stage of the disease and the patient’s overall condition. The mainstay of treatment is surgical resection with D2 lymphadenectomy and adjuvant or neoadjuvant radio- and chemotherapy. Currently, radiation therapy is widely used in several critical areas of gastric cancer treatment. Aim: The aim of this study is to evaluate the current use and effectiveness of radiotherapy in the treatment of gastric cancer, as well as the prospects for the further development of this therapeutic method. Material and methods: This study is based on a systematic review of several dozen scientific publications identified through PubMed and Google Schoolar databases using keywords “gastric cancer”, “radiotherapy”, “chemoradiotherapy”. Conclusions: In clinical practice, radiotherapy is primarily used as an adjuvant treatment. In perioperative therapy, it is combined with chemotherapy before surgery to reduce tumor size and after surgery to reduce the risk of recurrence and the development of micrometastases. Additionally, it is used as a palliative treatment for patients with advanced-stage disease who are not eligible for surgery. Emerging evidence also suggests potential benefits of incorporating radiotherapy into the management of patients with limited metastatic disease.
- Open Access
- 14 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
ROTATIONAL STABILITY AFTER ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION COMBINED WITH ANTEROLATERAL AUGMENTATION
Background and Objective: Residual rotational instability after anterior cruciate ligament reconstruction remains a clinically relevant problem, particularly in young and active patients returning to cutting and pivoting sports. This structured narrative review evaluates whether anterior cruciate ligament reconstruction combined with anterolateral augmentation improves rotational stability compared with isolated reconstruction. Methods: A structured PubMed search was conducted for English-language studies published between 2013 and 2025 addressing anterior cruciate ligament reconstruction, anterolateral ligament reconstruction, lateral extra-articular tenodesis, rotational instability, and pivot shift. Comparative clinical studies, randomized trials, systematic reviews, meta-analyses, and relevant biomechanical investigations were prioritized. Results: Current evidence suggests that combined reconstruction provides more consistent pivot-shift control than isolated anterior cruciate ligament reconstruction, especially in selected high-risk groups such as young athletes, patients with high-grade pivot shift, and selected revision cases. Randomized and pooled evidence also indicates reduced graft failure rates in some high-risk cohorts, although patient-reported functional outcomes are often similar between isolated and combined procedures. Conclusions: Combined anterior cruciate ligament reconstruction with anterolateral augmentation may enhance rotational stability and reduce failure risk in selected patients. However, routine use in all primary reconstructions cannot be recommended without stronger standardized long-term evidence.
- 14 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessROTATIONAL STABILITY AFTER ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION COMBINED WITH ANTEROLATERAL AUGMENTATION
Background and Objective: Residual rotational instability after anterior cruciate ligament reconstruction remains a clinically relevant problem, particularly in young and active patients returning to cutting and pivoting sports. This structured narrative review evaluates whether anterior cruciate ligament reconstruction combined with anterolateral augmentation improves rotational stability compared with isolated reconstruction. Methods: A structured PubMed search was conducted for English-language studies published between 2013 and 2025 addressing anterior cruciate ligament reconstruction, anterolateral ligament reconstruction, lateral extra-articular tenodesis, rotational instability, and pivot shift. Comparative clinical studies, randomized trials, systematic reviews, meta-analyses, and relevant biomechanical investigations were prioritized. Results: Current evidence suggests that combined reconstruction provides more consistent pivot-shift control than isolated anterior cruciate ligament reconstruction, especially in selected high-risk groups such as young athletes, patients with high-grade pivot shift, and selected revision cases. Randomized and pooled evidence also indicates reduced graft failure rates in some high-risk cohorts, although patient-reported functional outcomes are often similar between isolated and combined procedures. Conclusions: Combined anterior cruciate ligament reconstruction with anterolateral augmentation may enhance rotational stability and reduce failure risk in selected patients. However, routine use in all primary reconstructions cannot be recommended without stronger standardized long-term evidence.
- Open Access
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
THE ROLE OF BRACHYTHERAPY IN THE TREATMENT OF NON-MELANOMA SKIN CANCERS: A NARRATIVE REVIEW
Background. Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC) are the two most frequent malignancies worldwide, and their incidence continues to rise with the ageing of the population. Although surgical excision remains the gold standard, radiotherapy — including brachytherapy — constitutes a valuable alternative in selected clinical situations, particularly in elderly patients and in tumours located in cosmetically or functionally sensitive areas. Aim. This narrative review aims to define the role of brachytherapy in the treatment of non-melanoma skin cancers, with emphasis on currently used techniques (surface, contact, mould-based, and interstitial methods, including Leipzig- and Valencia-type applicators and electronic brachytherapy), as well as on indications, patient selection, efficacy, and safety profile. Methods. The PubMed/MEDLINE and Google Scholar databases were searched for English-language publications, and 44 articles published between 2011 and 2025 were included and analysed descriptively. Conclusions. The available literature indicates that brachytherapy is an effective treatment strategy for selected non-melanoma skin cancers, providing high local control rates (reported between 71% and 99%), good cosmetic outcomes, and low toxicity. High dose conformity and effective sparing of healthy tissue make brachytherapy a valuable component of multidisciplinary skin cancer care.
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
Open AccessTHE ROLE OF BRACHYTHERAPY IN THE TREATMENT OF NON-MELANOMA SKIN CANCERS: A NARRATIVE REVIEW
Background. Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC) are the two most frequent malignancies worldwide, and their incidence continues to rise with the ageing of the population. Although surgical excision remains the gold standard, radiotherapy — including brachytherapy — constitutes a valuable alternative in selected clinical situations, particularly in elderly patients and in tumours located in cosmetically or functionally sensitive areas. Aim. This narrative review aims to define the role of brachytherapy in the treatment of non-melanoma skin cancers, with emphasis on currently used techniques (surface, contact, mould-based, and interstitial methods, including Leipzig- and Valencia-type applicators and electronic brachytherapy), as well as on indications, patient selection, efficacy, and safety profile. Methods. The PubMed/MEDLINE and Google Scholar databases were searched for English-language publications, and 44 articles published between 2011 and 2025 were included and analysed descriptively. Conclusions. The available literature indicates that brachytherapy is an effective treatment strategy for selected non-melanoma skin cancers, providing high local control rates (reported between 71% and 99%), good cosmetic outcomes, and low toxicity. High dose conformity and effective sparing of healthy tissue make brachytherapy a valuable component of multidisciplinary skin cancer care.